Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
However, it is yet to be approved for any indications beyond glycemic control
In October 2024, the FDA formally took tirzepatide off its drug shortage list
What makes it relevant to obesity research
Signs and symptoms of overdose include CNS symptoms (dizziness, sensory and visual disturbances, and eventually convulsions) and cardiovascular effects (that range from hypertension and tachycardia to myocardial depression, hypotension, bradycardia, and asystole)
Eli Lilly, the pharmaceutical company that has developed tirzepatide, anticipates that in late 2023 the FDA will also approve use of Mounjaro/Zepbound as a weight loss medication in patients with obesity
US$ 28.47
US$ 27.46
US$ 29.64
US$ 24.95
US$ 24.51
US$ 29.90
US$ 29.10
US$ 27.50
